Contact
searchSearch
HMP Global
Login

Esophageal Cancer Resource Center

News
Neoadjuvant Chemotherapy Improves Survival Over Chemoradiation in Esophageal Cancer
06/09/2025
Grace Taylor, MS, MA
A large US National Cancer Database study shows neoadjuvant chemotherapy offers better survival than chemoradiation for operable esophageal adenocarcinoma.
A large US National Cancer Database study shows neoadjuvant chemotherapy offers better survival than chemoradiation for operable esophageal adenocarcinoma.
A large US National Cancer...
06/09/2025
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Esophageal Cancers
NCCN Updates Clinical Practice Guideline for Esophageal Cancers
03/10/2021
Janelle Bradley
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive...
03/10/2021
Journal of Clinical Pathways
The Impact of a Clinical Decision Support System for Advanced Gastric or Gastroesophageal Junction Cancer
Research Reports
The Impact of a Clinical Decision Support System for Advanced Gastric or Gastroesophageal Junction Cancer
12/16/2020
Anindya Chatterjee, PhD; Astra M. Liepa, PharmD; Marley Boyd, MS; Scott Paulson, MD; Kathleen M. Aguilar, MPH; Lisa M. Hess, PhD
Abstract: Gastric cancer treatment heterogeneity was assessed over successive updates of clinical pathways. Methods: Patient profiles, treatment patterns, and outcomes were assessed descriptively among adult...
Abstract: Gastric cancer treatment heterogeneity was assessed over successive updates of clinical pathways. Methods: Patient profiles, treatment patterns, and outcomes were assessed descriptively among adult...
...
12/16/2020
Journal of Clinical Pathways
Research Reports
Quality Improvement Pilot Project to Standardize a Prehabilitation Program for Patients With Esophageal Cancer Receiving Neoadjuvant Chemoradiation
12/17/2019
Karyn Goodman, MD, MS; Megan D. Marsh, PA; S. Lindsey Davis, MD; Lisa J. Wingrove, RD; Ashley E. Glode, PharmD, BCOP; Supriya K. Jain, MD; Lindel C.K. Dewberry, MD; Martin D. McCarter, MD; Michelle Bunch, CSW; Tracey E. Schefter, MD; Laura Melton, PhD
Abstract: A standard treatment recommendation for esophageal cancer patients with stage IB-IIIB disease is for neoadjuvant chemoradiation followed by surgery. This trimodality therapy can be difficult for patients...
Abstract: A standard treatment recommendation for esophageal cancer patients with stage IB-IIIB disease is for neoadjuvant chemoradiation followed by surgery. This trimodality therapy can be difficult for patients...
...
12/17/2019
Journal of Clinical Pathways
Research in Review
Treatment Better Than Observation for Older Patients With Esophageal Cancer
05/03/2017
Patients aged 80 years or older with early-stage esophageal cancer who received treatment had an increased 5-year overall survival (OS) compared with those who received no treatment or observation alone,...
Patients aged 80 years or older with early-stage esophageal cancer who received treatment had an increased 5-year overall survival (OS) compared with those who received no treatment or observation alone,...
...
05/03/2017
Journal of Clinical Pathways
Research in Review
PET Scans During Induction Chemo Contribute to Complete Response for Esophageal Cancer
01/19/2017
Positron emission tomography (PET) scans during induction chemotherapy for esophageal cancer helps assess patient response to treatment and adjust their therapy, which could lead to an improved complete response rate...
Positron emission tomography (PET) scans during induction chemotherapy for esophageal cancer helps assess patient response to treatment and adjust their therapy, which could lead to an improved complete response rate...
...
01/19/2017
Journal of Clinical Pathways
Research in Review
Esophageal Cancer Actually 3 Distinct Diseases
09/09/2016
A study published in Nature Genetics claims that esophageal cancer may in fact be 3 distinct diseases, which could pave the way for new methods of diagnosis and spur the development of targeted treatment...
A study published in Nature Genetics claims that esophageal cancer may in fact be 3 distinct diseases, which could pave the way for new methods of diagnosis and spur the development of targeted treatment...
A...
09/09/2016
Journal of Clinical Pathways
Research in Review
Nutritional Status an Indicator of Survival in Patients With Esophageal Cancer
05/25/2016
Nutritional status may be a prominent indicator of survival in elderly patients with esophageal cancer, claims a recently published study. Esophageal cancer is one of the leading causes of cancer-related death...
Nutritional status may be a prominent indicator of survival in elderly patients with esophageal cancer, claims a recently published study. Esophageal cancer is one of the leading causes of cancer-related death...
...
05/25/2016
Journal of Clinical Pathways
Research in Review
Positron Emission Tomography Overused in Patients With Lung and Esophageal Cancers
02/26/2016
A study finding significant variation in the use of positron emission tomography (PET) scans, but no association between the number of scans and improved 2-year survival, suggests that the imaging technique might be...
A study finding significant variation in the use of positron emission tomography (PET) scans, but no association between the number of scans and improved 2-year survival, suggests that the imaging technique might be...
A...
02/26/2016
Journal of Clinical Pathways

Expert Insights

Headshots
Interview
Endometrial Cancer Risk Research Suggests Earlier Intervention Across Age Groups
09/17/2025
Mengmeng Du, ScD, MSc; Noah C. Peeri, PhD, MPH
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer...
09/17/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Second Opinions in Oncology: Quality, Communication, and Patient Confidence
09/16/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down...
09/16/2025
Cancer Care Business Exchange
Golla Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
09/10/2025
Vishnukamal Golla, MD, MPH
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal...
09/10/2025
Journal of Clinical Pathways
Thawani Headshot
Videos
Progression-Free Survival in NSCLC: Clinical Utility, Limitations, and Evolving Standards
08/28/2025
Rajat Thawani, MD
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key...
08/28/2025
Journal of Clinical Pathways
Blog
CPC+CBEx 2025 Abstracts: Business Models, Breakthrough Tools, and Data-Driven Decisions Driving the Future of Cancer Care
08/27/2025
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways...
08/27/2025
Journal of Clinical Pathways
Wilfong Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/20/2025
Lalan Wilfong, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/20/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Developing a National Pathway Framework for Prostate Cancer: Insights From Solaris Health
08/15/2025
Jason Hafron, MD
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how...
08/15/2025
Journal of Clinical Pathways
Jennifer Woyach, MD
Interview
Overcoming Resistance to Targeted Therapies in CLL Through Personalized Treatment Approaches
08/13/2025
Jennifer Ann Woyach, MD
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores...
08/13/2025
Journal of Clinical Pathways
Henschel
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/13/2025
Rhonda Henschel, MBA
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/13/2025
Journal of Clinical Pathways
Arrowsmith Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/08/2025
Edward Arrowsmith, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/08/2025
Journal of Clinical Pathways

Newsfeed

News
Neoadjuvant Chemotherapy Improves Survival Over Chemoradiation in Esophageal Cancer
06/09/2025
Grace Taylor, MS, MA
A large US National Cancer Database study shows neoadjuvant chemotherapy offers better survival than chemoradiation for operable esophageal adenocarcinoma.
A large US National Cancer Database study shows neoadjuvant chemotherapy offers better survival than chemoradiation for operable esophageal adenocarcinoma.
A large US National Cancer...
06/09/2025
Journal of Clinical Pathways
News
HHS Final Rule Expands Real-Time Prescription Access, Eases Prior Authorization Burdens
09/26/2025
Grace Taylor, MS, MA
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of...
09/26/2025
Journal of Clinical Pathways
Conference Coverage
Real-World Evidence in Oncology: Opportunities, Challenges, and Clinical Impact
09/10/2025
Grace Taylor, MS, MA
In this CPC+CBEx session, experts debate how real-world evidence can complement clinical trials, accelerate regulatory approvals, and reshape patient care.
In this CPC+CBEx session, experts debate how real-world evidence can complement clinical trials, accelerate regulatory approvals, and reshape patient care.
In this CPC+CBEx session,...
09/10/2025
Journal of Clinical Pathways
Conference Coverage
Building a Transparent Framework for Predictable Cost of Care in Oncology Pathways
09/10/2025
Hannah Musick
The Predictable Cost of Care initiative is creating a transparent, standardized model to quantify the true, incremental costs of cancer therapies—enabling more informed, equitable, and efficient decision-making across pathways, payers, and...
The Predictable Cost of Care initiative is creating a transparent, standardized model to quantify the true, incremental costs of cancer therapies—enabling more informed, equitable, and efficient decision-making across pathways, payers, and...
The Predictable Cost of Care...
09/10/2025
Journal of Clinical Pathways
Conference Coverage
Reviewing a Decade of Oncology Pathways: Standardization, Gaps, and the Road to Real-Time Intelligence
09/09/2025
Hannah Musick
A decade after the American Society of Clinical Oncology’s (ASCO’s) original guidance, oncology pathways are maturing into powerful tools for standardizing care, but gaps in disease coverage, workflow integration, and real-time adaptability...
A decade after the American Society of Clinical Oncology’s (ASCO’s) original guidance, oncology pathways are maturing into powerful tools for standardizing care, but gaps in disease coverage, workflow integration, and real-time adaptability...
A decade after the American...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
AI as a Thought Partner: Reframing Innovation in Medicine and Practice Management
09/09/2025
Grace Taylor, MS, MA
In this panel from CPC+CBEx, experts explore how artificial intelligence (AI) is emerging as a “thought partner” in health care, helping clinicians and practices manage rising complexity and improve outcomes while preserving the human touch...
In this panel from CPC+CBEx, experts explore how artificial intelligence (AI) is emerging as a “thought partner” in health care, helping clinicians and practices manage rising complexity and improve outcomes while preserving the human touch...
In this panel from CPC+CBEx,...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
How AI is Reshaping Clinical Practice, Governance, and Patient Trust
09/09/2025
Grace Taylor, MS, MA
From streamlining documentation to reshaping prior authorization, a panel of experts reveal how artificial intelligence (AI) is changing the realities of cancer care—and the challenges that come with it.
From streamlining documentation to reshaping prior authorization, a panel of experts reveal how artificial intelligence (AI) is changing the realities of cancer care—and the challenges that come with it.
From streamlining documentation...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
From Dispensing to Decision-Making: How Pharmacists Are Redefining Leadership in Oncology Care
09/08/2025
Grace Taylor, MS, MA
This session highlights how pharmacists are stepping into pivotal leadership roles, balancing science, business, and patient care to navigate the increasingly complex oncology treatment landscape.
This session highlights how pharmacists are stepping into pivotal leadership roles, balancing science, business, and patient care to navigate the increasingly complex oncology treatment landscape.
This session highlights how...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Theranostics: Clinical Promise, Operational Hurdles, and the Road Ahead
09/08/2025
Hannah Musick
Theranostics is rapidly emerging as a transformative, fifth pillar of cancer care—combining precision imaging and targeted radiopharmaceutical therapy—but its widespread adoption hinges on overcoming operational, financial, and infrastructure...
Theranostics is rapidly emerging as a transformative, fifth pillar of cancer care—combining precision imaging and targeted radiopharmaceutical therapy—but its widespread adoption hinges on overcoming operational, financial, and infrastructure...
Theranostics is rapidly emerging...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Scaling Bispecifics and CAR T-Cell Therapy in Community Oncology: From Promise to Practice
09/08/2025
Hannah Musick
A panel of oncology leaders urged community practices to take immediate, systematized steps to adopt bispecifics and CAR T-cell therapies—highlighting that without local access, the promise of these innovations may never reach the patients...
A panel of oncology leaders urged community practices to take immediate, systematized steps to adopt bispecifics and CAR T-cell therapies—highlighting that without local access, the promise of these innovations may never reach the patients...
A panel of oncology leaders...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Practical Insights for Embedding Whole-Person Care into Clinical Pathways
09/08/2025
Juliet Gallagher
A session at CPC+CBEx 2025 highlighted how structured triage, real-time care coordination, and non-clinical staff training can transform symptom management and reduce unnecessary acute care utilization in oncology.
A session at CPC+CBEx 2025 highlighted how structured triage, real-time care coordination, and non-clinical staff training can transform symptom management and reduce unnecessary acute care utilization in oncology.
A session at CPC+CBEx 2025...
09/08/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
JCP July-Aug Cover 2025

Current Issue

August 2025
Volume 11
Issue 4
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use